Advanced Cancer Genomics Institute: Genetic Signatures and Therapeutic Targets in Cancer Progression
Annual rept. 31 Sep 2013-31 Dec 2013
ROSWELL PARK CANCER INST BUFFALO NY
Pagination or Media Count:
Our aim is to develop multiple next-gen-based genomics analysis capabilities to be able to identify cancer-related signatures that predict progression to malignancy and that identify novel therapeutic pathways and targets. To this end, we are purchasing for the Advanced Cancer Genomics Institute within our Genomics Core resource Lab multiple next-gen instruments, including associated hardware and software platforms. Following the performance of quality-assurance testing, RPCI researchers will perform whole genome sequencingre-sequencing, exome-seq, transcriptome-seq, miRNA-seq, ChIPseq, microbiome-seq, virome-seq and copy number variationloss of heterozygosity CNVLOH analyses including the associated bioinformatics analyses. Based on the concentration of expertise at RPCI in prostate cancer pre-clinical and clinical models, most of the proposed work has been adapted to address genomic signatures of androgen receptor-driven progression to castration-recurrent prostate cancer CR-CaP. The capabilities of this Core will foster our goal of developing practical approaches to personalized cancer medicine. The long-term aim is to develop full-operational next-gen expertise to facilitate the collaboration of RPCI researchers with other members of the National Functional Genomics Consortium.
- Medicine and Medical Research